In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...

It was found that those with severe hemophilia B have less than 1% of normal factor IX activity, often experiencing spontaneous bleeding that can cause joint damage or life-threatening events.

The results of gene therapy for hemophilia B contrast with those of factor replacement therapies, where lifelong infusions ...

A study by UK-based scientists has confirmed that a gene transfer approach to treating haemophilia B remains safe and ...

Gene therapy has proved to be a safe long-term treatment for haemophilia B. The benefits of a single dose persist for at ...

The late-breaking abstracts presented on the last day of the 2025 European Hematology Association (EHA) Congress show “what a vibrant clinical specialty we’re in,” according to session cochair Brian ...

Our knowledge of the effects of space and low gravity on blood cells, clotting, and anemia continues to expand, but further ...

While commercial uptake by patients still lags and a recent court decision rekindles a legal battle, clinical successes ...

Successful immune tolerance induction (ITI) in hemophilia A patients with inhibitors led to lower treatment costs, a study ...

Columnist Jennifer Lynne argues that her health is not defined by her diagnoses, and in fact those terms can often be too limited.

In a major breakthrough, UK-based researchers have found that a one-time gene therapy approach for haemophilia B remains safe ...

Learn how clotting factor therapy, gene therapy, and non-factor treatments are improving hemophilia prognosis and life expectancy.